StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.53−0.03 (-1.92%)

Close on Nov 17, 2026Market cap $297.61MP/E –Yield –

Altimmune revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Altimmune's revenue for the twelve months ending Dec 31, 2025 was $41.00K, up 105.0% year over year. For fiscal 2025 it was $41.00K, up 105.0% from the year before. Over ten years it grew -47.2% a year on average. The highest annual figure on record is $24.27M in fiscal 2011.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.00K+105.0%
FY2024Dec 31, 2024$20.00K-95.3%
FY2023Dec 31, 2023$426.00K–
FY2022Dec 31, 2022-$68.00K-101.5%
FY2021Dec 31, 2021$4.41M-46.1%
FY2020Dec 31, 2020$8.19M+41.1%
FY2019Dec 31, 2019$5.80M-43.8%
FY2018Dec 31, 2018$10.33M-3.8%
FY2017Dec 31, 2017$10.74M+231.8%
FY2016Dec 31, 2016$3.24M-86.7%
FY2011Dec 31, 2011$24.27M+15.6%
FY2010Dec 31, 2010$20.99M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$26.00K+420.0%
Q3 FY2025Sep 30, 2025$5.00K0.0%
Q2 FY2025Jun 30, 2025$5.00K0.0%
Q1 FY2025Mar 31, 2025$5.00K0.0%
Q4 FY2024Dec 31, 2024$5.00K-86.5%
Q3 FY2024Sep 30, 2024$5.00K-98.6%
Q2 FY2024Jun 30, 2024$5.00K-16.7%
Q1 FY2024Mar 31, 2024$5.00K-76.2%
Q4 FY2023Dec 31, 2023$37.00K+1750.0%
Q3 FY2023Sep 30, 2023$362.00K+4425.0%
Q2 FY2023Jun 30, 2023$6.00K-81.3%
Q1 FY2023Mar 31, 2023$21.00K-99.4%
Q3 FY2022Sep 30, 2022$2.00K-98.7%
Q2 FY2022Jun 30, 2022$8.00K-94.2%
Q1 FY2022Mar 31, 2022$32.00K-96.2%
Q4 FY2021Dec 31, 2021$3.28M+41.7%
Q3 FY2021Sep 30, 2021$158.00K-94.6%
Q2 FY2021Jun 30, 2021$137.00K-81.0%
Q1 FY2021Mar 31, 2021$838.00K-62.1%
Q4 FY2020Dec 31, 2020$2.31M+301.7%
Q3 FY2020Sep 30, 2020$2.94M+356.2%
Q2 FY2020Jun 30, 2020$721.64K-55.6%
Q1 FY2020Mar 31, 2020$2.21M-25.1%
Q4 FY2019Dec 31, 2019$575.80K-77.8%
Q3 FY2019Sep 30, 2019$643.98K-75.6%
Q2 FY2019Jun 30, 2019$1.63M-32.7%
Q1 FY2019Mar 31, 2019$2.96M+9.8%
Q4 FY2018Dec 31, 2018$2.59M-7.8%
Q3 FY2018Sep 30, 2018$2.63M-42.6%
Q2 FY2018Jun 30, 2018$2.42M-20.4%
Q1 FY2018Mar 31, 2018$2.69M+798.3%
Q4 FY2017Dec 31, 2017$2.81M+159.1%
Q3 FY2017Sep 30, 2017$4.59M+409.6%
Q2 FY2017Jun 30, 2017$3.04M–
Q1 FY2017Mar 31, 2017$299.57K–
Q4 FY2016Dec 31, 2016$1.08M–
Q3 FY2016Sep 30, 2016$901.04K–

More Altimmune figures

See a number that looks wrong?